Showing 921-930 of 1604 results for "".
- ACAAI News: 72% of AD Patients Report Poor Mental Health for 1-10 Days in the Past Monthhttps://practicaldermatology.com/news/acaai-news-72-of-ad-patients-report-poor-mental-health-for-1-10-days-in-the-past-month/2462129/Folks with atopic dermatitis (AD) are more likely to report poor mental health than their counterparts without the inflammatory skin condition, new research shows. The study, which was presented at the 2023 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientif
- ACR Update: TAK-279 Shows Promise in Phase 2b Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/acr-update-tak-279-shows-promise-in-phase-2b-psoriatic-arthritis-study/2462119/Takeda's investigational tyrosine kinase 2 (TYK2) inhibitor TAK-279 showed significant efficacy in patients with active psoriatic arthritis, according to Phase 2b data slated to be presented at the American College of Rheumatology's (ACR) annual meeting in San Diego, California.
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- Exploring the Sunscreen Paradoxhttps://practicaldermatology.com/news/exploring-the-sunscreen-paradox/2462101/Sunscreen use may provide people with a false sense of security. The so-called sunscreen paradox suggests that individuals with higher levels of sun exposure also tend to use more but not an adequate quantity of sunscreen or other sun-protection measures, providing a false sense of
- Allergan Reports Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lineshttps://practicaldermatology.com/news/allergan-reports-positive-topline-results-from-studies-of-trenibotulinumtoxine-for-glabellar-lines/2462093/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- TREMFYA (Guselkumab) Improves PsO Symptoms Across All Skin Toneshttps://practicaldermatology.com/news/tremfya-guselkumab-improves-pso-symptoms-across-all-skin-tones/2462086/TREMFYA demonstrated significant skin clearance, rapid scalp psoriasis clearance and improvement in health-related quality of life outcomes in psoriasis patients across all skin tones, according to results from Cohort A of the VISIBLE trial. This study, which was presented at the
- VTAMA (Tapinarof) Cream, 1% Shows Efficacy in Patients With Intertriginous Plaque Psoriasishttps://practicaldermatology.com/news/vtama-tapinarof-cream-1/2462085/VTAMA (tapinarof) Cream, 1% performed well in intertriginous plaque psoriasis (iPsO), according to new Phase 4 data presented at the 43rd Annual Fall Clinical Dermatology Conference in Las Vegas. This Phase 4 study expands the body of data for VTAMA cream in adult plaque
- Aquaphor Partners with NBCUniversal and Giselle Blondet for New Campaignhttps://practicaldermatology.com/news/aquaphor-partners-with-nbcuniversal-and-telemundo-personality-giselle-blondet-for-new-campaign/2462084/Aquaphor is partnering with NBCUniversal and Telemundo personality Giselle Blondet to showcase the multiple uses of Aquaphor Baby Healing Ointment across generations. "Aquaphor Baby has been part of our family for many years. What you see is a perfect reflection of my rel
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i